Skip to main content
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America logoLink to Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
. 2021 Feb 12;72(9):1684–1685. doi: 10.1093/cid/ciaa1767

Corrigendum to: Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies

PMCID: PMC8096209  PMID: 33576382

In the originally published version of this article [Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. Clin Infect Dis 2019;68(12):2135–2143. https://doi.org/10.1093/cid/ciy920], the summary meta-analysis findings were listed as:

63.5% (95% CI, 37.3%–89.7%) with study weights of 45.31, 14.23, 27.14, and 13.32 for studies 1, 2, 3, and 4, respectively, and I2 = 15.7% (P = .313; Figure 2) for the main pooled PCV13 vaccine effectiveness (VE) estimate against serotype 3 IPD from the random-effects meta-analysis, and 72.4% (95% CI, 56.7%–88.0%) with study weights of 23.13, 11.80, 64.25, and 0.81 for studies 1, 3, 5, and 6, respectively, and I2 of 0% (P = .891; Figure 3) for the random-effects sensitivity analysis that included conference posters.

These estimates should instead be listed as:

50.5% (95% CI, 8.2%–73.3%) with study weights of 17.50, 33.39, 17.06, and 32.05 for studies 1, 2, 3, and 4, respectively, and I2 = 32.8% (P = .216; Figure 2) for the main pooled PCV13 VE estimate against serotype 3 IPD from the random-effects meta-analysis, and 69.1% (95% CI, 50.4%–80.8%) with study weights of 13.42, 12.98, 63.62, and 9.98 for studies 1, 3, 5, and 6, respectively, and I2 of 0% (P = .574; Figure 3) for the random-effects sensitivity analysis that included conference posters.

The corresponding revised figures are shown below.

graphic file with name ciaa1767f0001.jpg

Figure 2 (revised). Vaccine effectiveness against serotype 3 invasive pneumococcal disease including only published studies with nonoverlapping datasets. Abbreviations: CI, Confidence interval; VE, vaccine effectiveness. aVE for at least 2 doses before 12 months or 1 dose on or after 12 months. bVE for at least 1 dose.

graphic file with name ciaa1767f0002.jpg

Figure 3 revised. Vaccine effectiveness for at least 1 dose of 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal disease including published and unpublished studies with nonoverlapping datasets. Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

The details have been corrected only in this corrigendum to preserve the published version of record. The authors apologize for any inconvenience this may have caused.


Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES